Targeting Circular RNAs (circRNAs) in Atherosclerosis Using CRISPR Technology.

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Gene Editing Technology

Background:

• Atherosclerosis is a major cause of cardiovascular disease, driven by chronic inflammation.
• Circular RNAs (circRNAs) regulate key processes in inflammation, lipid metabolism, and plaque stability relevant to atherosclerosis.
• Specific circRNAs like circANRIL, circHIPK, and circRSF1 are implicated in atherosclerosis development.

Purpose of the Study:

• To review the biogenesis and functions of circRNAs in atherosclerosis.
• To explore the application of CRISPR-Cas technology (Cas9 and Cas13) in studying and potentially treating atherosclerosis.
• To discuss the potential of circRNA-based therapies and CRISPR-Cas13 for atherosclerosis.

Main Methods:

• Review of existing literature on circRNAs and CRISPR-Cas technology in atherosclerosis research.
• Analysis of specific circRNAs (circANRIL, circHIPK, circRSF1) and their roles.
• Examination of CRISPR-Cas9 applications for lipid metabolism modification and CRISPR-Cas13 for RNA-level intervention.

Main Results:

• CRISPR-Cas9 enables targeting genes like PCSK9, LDLR, and APOB to modulate lipid metabolism and treat conditions like familial hypercholesterolemia in atherosclerosis models.
• CRISPR-Cas13 offers a novel RNA-targeting strategy for selective circRNA editing to regulate atherosclerosis-related pathways.
• Specific circRNAs significantly influence atherosclerosis progression and development.

Conclusions:

• CircRNA research and CRISPR innovation hold revolutionary potential for atherosclerosis treatment.
• Further research is needed to elucidate circRNA mechanisms and develop effective CRISPR-Cas13 delivery systems.
• Extensive preclinical validation is crucial to translate these findings into clinical applications for cardiovascular disease.